Other preclinical studies in models of neovascular eye diseases have shown that the systemic administration of AKB-9778, a small-molecule agonist of the angiopoietin receptor Tie2, stabilizes the vasculature against multiple permeability factors, thus reducing vascular leakage and retinal neovascularization. Here, TEK is linked to eye disorder.